Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease

Journal of Cardiovascular Pharmacology
Gorm Boje JensenCLARICOR Trial Group

Abstract

In the CLARICOR trial, significantly increased cardiovascular (CV) and all-cause mortality in stable patients with coronary heart disease were observed after a short course of clarithromycin. We report on the impact of statin treatment at entry on the CV and all-cause mortality. The multicenter CLARICOR trial randomized patients to oral clarithromycin (500 mg daily; n = 2172) versus matching placebo (daily; n = 2201) for 2 weeks. Patients were followed through public databases. In the 41% patients on statin treatment at entry, no significant effect of clarithromycin was observed on CV (hazard ratio [HR], 0.68, 95% confidence interval [CI], 0.38-1.22; P = 0.20) or all-cause mortality (HR, 1.08; 95% CI, 0.71-1.65; P = 0.72) at 2.6-year follow up. In the patients not on statin treatment at entry, clarithromycin was associated with a significant increase in CV (HR, 1.90; 95% CI, 1.34-2.67; P = 0.0003; statin-clarithromycin interaction P = 0.0029) and all-cause mortality (HR, 1.33; 95% CI, 1.05-1.67; P = 0.016; statin-clarithromycin interaction P = 0.41). Multivariate analysis and 6-year follow up confirmed these results. Concomitant statin treatment in stable patients with coronary heart disease abrogated the observed increased CV ...Continue Reading

References

Jan 15, 2000·Journal of the American College of Cardiology·C J VaughanC T Basson
Nov 25, 2000·Cardiovascular Research·O J de BoerA E Becker
Dec 18, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·G K Hansson
Mar 12, 2003·Circulation·Ralf ZahnUNKNOWN Working Group of Leading Hospital Cardiologists
Sep 18, 2003·JAMA : the Journal of the American Medical Association·Christopher M O'ConnorUNKNOWN Investigators in the WIZARD Study
Jan 7, 2005·The New England Journal of Medicine·Steven E NissenUNKNOWN Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators
Apr 22, 2005·The New England Journal of Medicine·J Thomas GraystonUNKNOWN ACES Investigators
Apr 22, 2005·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Jun 2, 2005·JAMA : the Journal of the American Medical Association·Richard AndrawsDavid L Brown
Jul 19, 2006·Annals of Internal Medicine·Kevin DouglasJeffrey L Jackson
Nov 7, 2006·Journal of the American College of Cardiology·Nobuhiro TaharaTsutomu Imaizumi

❮ Previous
Next ❯

Citations

Jul 16, 2014·Scandinavian Journal of Clinical and Laboratory Investigation·Mette BjerreUNKNOWN Claricor Trial Group
Oct 26, 2010·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Naja Dam MygindUNKNOWN CLARICOR Trial Group
Jan 19, 2019·The Cochrane Database of Systematic Reviews·Malene Plejdrup HansenChris B Del Mar
Dec 6, 2011·Cardiovascular Therapeutics·Jun-ichi SuzukiMitsuaki Isobe
Apr 12, 2017·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Angel Y S WongIan C K Wong
Dec 14, 2011·The New England Journal of Medicine·David L Hahn
Mar 12, 2021·The Cochrane Database of Systematic Reviews·Naqash J SethiJanus C Jakobsen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.